TY - JOUR
T1 - ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome
AU - Goyal, Amrita
AU - O'Leary, Daniel
AU - Dabaja, Bouthaina
AU - Weng, Wen Kai
AU - Zain, Jasmine
AU - Cutler, Corey
AU - Guitart, Joan
AU - Kim, Youn H.
AU - Geskin, Larisa J.
AU - Hoppe, Richard T.
AU - Wilson, Lynn D.
AU - Beaven, Anne W.
AU - Horwitz, Steve
AU - Allen, Pamela B.
AU - Barta, Stefan K.
AU - Bohjanen, Kimberly
AU - Brammer, Jonathan E.
AU - Carter, Joi B.
AU - Comfere, Nneka
AU - DeSimone, Jennifer A.
AU - Dusenbery, Kathryn
AU - Duvic, Madeleine
AU - Huen, Auris
AU - Jagadeesh, Deepa
AU - Kelsey, Chris R.
AU - Khodadoust, Michael S.
AU - Lechowicz, Mary Jo
AU - Mehta-Shah, Neha
AU - Moskowitz, Alison J.
AU - Olsen, Elise A.
AU - Poh, Christina
AU - Pro, Barbara
AU - Querfeld, Christiane
AU - Sauter, Craig
AU - Sokol, Lubomir
AU - Sokumbi, Olayemi
AU - Wilcox, Ryan A.
AU - Zic, John A.
AU - Hamadani, Mehdi
AU - Foss, Francine
N1 - Publisher Copyright:
© 2024 The American Society for Transplantation and Cellular Therapy
PY - 2024/11
Y1 - 2024/11
N2 - Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL). While MF generally follows an indolent course, a subset of patients will experience progressive and/or treatment-refractory disease; Sézary syndrome is an aggressive lymphoma associated with high morbidity and mortality. Although allogeneic hematopoietic cell transplant (allo-HCT) is the only currently available potentially curative treatment modality for MF/SS there is no published guidance on referral criteria, transplant timing orallo-HCT approach. To develop consensus clinical practice recommendations, we performed a Delphi survey of 32 specialists in dermatology (n = 9), transplant hematology/oncology (n = 10), non-transplant hematology/oncology (n = 8), and radiation oncology (n = 5) from across the United States. Consensus required agreement of ≥75% of participants. Sixteen consensus statements were generated on four topics: (1) criteria for referral for consideration for allo-HCT, (2) allo-HCT preparative regimens and procedures (3) disease status at the time of allo-HCT, and (4) multidisciplinary management in the pre- and post-transplant settings. These clinical practice guidelines provide a framework for decision-making regarding allo-HCT for MF/SS and highlight areas for future prospective investigation.
AB - Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL). While MF generally follows an indolent course, a subset of patients will experience progressive and/or treatment-refractory disease; Sézary syndrome is an aggressive lymphoma associated with high morbidity and mortality. Although allogeneic hematopoietic cell transplant (allo-HCT) is the only currently available potentially curative treatment modality for MF/SS there is no published guidance on referral criteria, transplant timing orallo-HCT approach. To develop consensus clinical practice recommendations, we performed a Delphi survey of 32 specialists in dermatology (n = 9), transplant hematology/oncology (n = 10), non-transplant hematology/oncology (n = 8), and radiation oncology (n = 5) from across the United States. Consensus required agreement of ≥75% of participants. Sixteen consensus statements were generated on four topics: (1) criteria for referral for consideration for allo-HCT, (2) allo-HCT preparative regimens and procedures (3) disease status at the time of allo-HCT, and (4) multidisciplinary management in the pre- and post-transplant settings. These clinical practice guidelines provide a framework for decision-making regarding allo-HCT for MF/SS and highlight areas for future prospective investigation.
UR - http://www.scopus.com/inward/record.url?scp=85206114463&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85206114463&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2024.08.020
DO - 10.1016/j.jtct.2024.08.020
M3 - Article
C2 - 39222792
AN - SCOPUS:85206114463
SN - 2666-6375
VL - 30
SP - 1047
EP - 1060
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
IS - 11
ER -